Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23940236 | 0.86 | CREBBP (0.51) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL9165502 | 0.84 | HTR2C (0.61) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL22810515 | 0.81 | MEN1 (0.56) | TSHRALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL19276665 | 0.76 | SMN1; SMN2 (0.63) | ALDH1A1KDM4EMEN1HPGDKMT2A | |
| SCHEMBL15458754 | 0.74 | SMN1; SMN2 (0.51) | ALDH1A1KDM4EMEN1KMT2ANPC1 | |
| SCHEMBL23940249 | 0.73 | BRD4 (0.55) | ALDH1A1KDM4E | |
| SCHEMBL23940153 | 0.73 | ALDH1A1 (0.50) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18132518 | 0.72 | ALDH1A1 (0.72) | TSHRALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL27874715 | 0.72 | ALDH1A1 (0.63) | TSHRALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL3924368 | 0.72 | ALDH1A1 (0.53) | ALDH1A1KDM4EHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | TYK2, JAK3, JAK1 | TSHR 837/4885ALDH1A1 2637/4885KDM4E 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.